Key result
Percutaneous transfemoral TAVR induced significant common femoral artery shrinkage, reducing minimum luminal diameter from 6.8 mm to 5.6 mm (P<.001).
Why the study?
Does percutaneous transfemoral TAVR reduce common femoral artery minimum luminal diameter in patients undergoing the procedure?
Cohort (n=124)
Does percutaneous transfemoral TAVR reduce common femoral artery minimum luminal diameter in patients undergoing the procedure?
Absolute Event Rate: 5.6% vs 6.8%
p-value: p=<.001
Percutaneous transfemoral TAVR induces significant angiographically detectable common femoral artery lumen reduction, highlighting a potential new side effect of the procedure.
Transfemoral TAVR may cause detectable femoral artery narrowing; this Level 3 finding leaves open its clinical impact and need for confirmation.
OBJECTIVES: We sought to investigate the possible impact of transaortic valve replacement (TAVR) on common femoral artery (CFA) integrity as assessed by angiography. BACKGROUND: CFA represents the most adopted access for TAVR but various degrees of vascular damage may be induced by the procedure. METHODS: Patients underwent percutaneous transfemoral TAVR who had both pre- and post-TAVR access-site angiography were retrospectively selected. Clinical and procedural data (including technique and complications) were prospectively recorded into a structured TAVR database. Pre-TAVR and post-TAVR angiograms were analyzed using a quantitative angiographic analysis software to assess reference diameters, minimum luminal diameter (MLD), and percentage of diameter stenosis (DS). RESULTS: A total of 124 patients entered the study (mean age: 85 years, mean Euroscore II: 10%). ProStar (13.5%) and double ProGlide (82.2%) preclosure were the main hemostatic techniques. CFA exhibited a significant shrinkage with TAVR as assessed by significant MLD reduction (5.6 mm after TAVR vs. 6.8 mm before, P < .001) and DS increase (30.3% after vs. 17.0%, P < .001). Such differences remained statistically significant after exclusion of 18 patients (14.2%) who had (minor or major) vascular complications. At multivariable analysis, pre-TAVR DS (P = .03) and history of peripheral arterial disease (P = .01), were significantly associated with vascular complications. CONCLUSIONS: Percutaneous TAVR induces an angiographically detectable CFA lumen reduction. Such findings call for further studies assessing clinical impact of this phenomenon and open the door for further refinements of the TAVR access management aimed at preserving vessel integrity.
No takes yet. Share an insight, caveat, or question.
Shoeib et al. (2017) conducted a cohort in Patients undergoing transcatheter aortic valve replacement (n=124). Percutaneous transfemoral transcatheter aortic valve replacement (TAVR) vs. Pre-TAVR baseline was evaluated on Minimum luminal diameter (MLD) of the common femoral artery (p=<.001). Percutaneous transfemoral TAVR induced significant common femoral artery shrinkage, reducing minimum luminal diameter from 6.8 mm to 5.6 mm (P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: